Drugs that contain Pafolacianine Sodium

1. List of Cytalux drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9333270 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US9061057 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US10881747 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US9789208 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US9341629 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US9254341 ON TARGET LABS Methods of manufacture of pteroyl-amino acid-fluorescent dyes
Oct, 2033

(10 years from now)

Do you want to check out CYTALUX patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 29, 2026
New Indication (I) Dec 16, 2025
Orphan Drug Exclusivity (ODE) Nov 29, 2028

NCE-1 date: 2025-11-29

Market Authorisation Date: 29 November, 2021

Treatment: Cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CYTALUX family patents

16

United States

5

Japan

4

Australia

3

China

3

Israel

3

Canada

3

Mexico

3

European Union

1

Spain

1

Hong Kong

1

Brazil

EA

1

EA

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic